New Product Expands Support for Growing Radiopharmaceutical Market
Idaho Falls, Idaho, June 2, 2025 – International Isotopes Inc. (OTCQB: INIS), is pleased to announce the commercial availability of Ytterbium-176 (Yb-176), a stable isotope used in the production of Lutetium-177 (Lu-177) — a critical therapeutic radionuclide in targeted cancer treatments.
Yb-176 is a key precursor in the production of Lu-177 via neutron irradiation. With increasing demand for targeted radiopharmaceuticals across the globe, the availability of high-purity Yb-176 supports both current clinical applications and future growth in precision oncology.
“The launch of Yb-176 marks a significant step in our commitment to advancing nuclear medicine,” said Shahe Bagerdjian, President and CEO of International Isotopes Inc. “As the industry moves rapidly toward more personalized and effective radiotherapeutics, we are proud to support our partners with the critical materials they need.”
For more information, visit: https://intisoid.com/yb-176/
International Isotopes Contact:
admin@intisoid.com
intisoid.com
208.524.5300